A year of ups and downs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A year of ups and downs


Pharmaceutical Technology Europe
Volume 22, Issue 12


Fedra Pavlou
So 2010 is nearly over and what a year it's been for our industry. We've borne witness to the dramatic changes that have been spurred by the financial crisis of 2008/09: the spate of announcements regarding job losses; the myriad of headlines hinting at or confirming still further M&A activity; the restructuring/diversification/divestiture of underperforming divisions; the rising interest in biologics, generics, outsourcing, the emerging markets; the continued drive to curb counterfeits and improve supply chain security, to name just a few of the recurring trends of 2010.

For the pharma/biopharma industry, I would define this year as one of refocusing and reprioritising. It will be interesting to see what these changes will yield moving into 2011. It's likely that companies will continue looking to the emerging countries as high growth markets and generics and biologics as potential acquisition targets, for those not already active in those areas. But I do hope that we'll see more investment in R&D in the next 12 months, and perhaps an increase in focus in personalised medicine and stem cell therapy research, seeing as both are hoped to play a greater role in the future of patient care. There's no doubt that originator companies will remain focused on protecting their valuable brands from generic competition, more likely through improved administration routes, so drug delivery and innovative dosage form manufacturers are set to reap the rewards of this trend.

There is one thing that I can guarantee for 2011 and that is that we at PTE will be there to continue reporting on all of the latest trends, innovations and issues that matter to you through our magazine, website, eNewsletters, digital magazine and Twitter feeds. We will also continue listening to you and encouraging you to share your views with your peers through our LinkedIn group which, at the time of writing, now has 1130 members! It's clear that you want to share ideas with like-minded peers so why not join our group, if you haven't already done so, and start sharing ( http://www.pharmtech.com/linkedin).

I would like to thank you for your continued support of PTE in 2010 and I look forward to an eventful 2011.

Fedra Pavlou, Editor-in-Chief

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
29%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
13%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology Europe,
Click here